Coombe, chairman of the FTSE 100 finance directors group, will sit on the main board of a company that will have a combined market capitalisation of approximately £114bn. It will be one of Europe’s largest companies by market capitalisation.
The deal is expected to be completed by the summer. The two companies are thought to have resumed merger talks because a big obstacle to a smooth marriage will be removed when SmithKline chief executive Jan Leschly steps down in April.
Animosity between Leschly and Glaxo executive chairman Richard Sykes was seen as the main hurdle to an earlier pact.
The merger will create a group with combined sales from continuing businesses of approximately £15bn, and an estimated 7.3% share of the global pharmaceutical market.
The two partners, both of which are audited by PricewaterhouseCoopers, expect the deal to generate £1bn in annual pre-tax cost savings from the third anniversary of completion of which £250m is expected to be reinvested in R&D.
The second largest improvement in ‘significant’ levels of financial distress since the EU Referendum was in professional services, found research from Begbies Traynor
Just one half of UK practices have implemented a pricing structure around auto enrolment implementation and advice - with many suffering increased costs
Deloitte's north-west Europe foray; BDO, Smith & Williamson investment paths; Shelley Stock Hutter; and Wilkins Kennedy discussed by editor Kevin Reed on our Friday Afternoon Live broadcast
Accountants should alter their perspective on auto-enrolment to maximise business opportunities, according to Eric Clapton.